Siga Technologies INC Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
Siga Technologies INC (SIGA) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $1.60 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-07.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2017-03-07
- Siga Technologies INC adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2016 was $1.60M, a 0.00% change from fiscal 2015.
- Siga Technologies INC adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2015 was $1.60M, a 0.00% change from fiscal 2014.
- Siga Technologies INC adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2014 was $1.60M, a 0.00% change from fiscal 2013.
- Siga Technologies INC adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2013 was $1.60M, a 128.57% increase from fiscal 2012.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|
| 2016-12-31 | $1.60M 10-K · filed 2017-03-07 |
| 2015-12-31 | $1.60M 10-K · filed 2016-03-04 |
| 2014-12-31 | $1.60M 10-K · filed 2015-03-06 |
| 2013-12-31 | $1.60M 10-K · filed 2014-03-10 |
| 2012-12-31 | $700.00K 10-K/A · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |